Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS®), with commercial lipid-based formulations

International Journal of Pharmaceutics

Volumn 267, Issue 1-2, 2003, Pages 101-112

  Fukui, Hiroshi ^a   Koike, Tomohiro ^a   Nakagawa, Takashi ^a   Saheki, Akira ^a   Sonoke, Satoru ^a   Tomii, Yoshifumi ^a   Seki, Junzo ^a  

^a NIPPON SHINYAKU CO LTD   (Japan)

Author keywords

Abelcet; AmBisome; Amphocil; Amphotericin B; Fungizone; Nanoemulsions

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CARRAGEENAN; LIPID NANOSPHERE; LNS; MICROSPHERE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; LOW DRUG DOSE; MALE; NONHUMAN; PLEURISY; PRIORITY JOURNAL; RAT;

EID: 0242361226     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2003.08.002     Document Type: Article

References (29)

1. Adler-Moore J., Proffitt R.T. Development, characterization, efficacy and mode of action of AmBisome®, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3:1993;429-450.
2. Adler-Moore J., Proffitt R.T. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 49:2002;21-30.
3. Atkinson A.J., Bennett J.E. Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 13:1978;271-276.
4. Beck-Sagué C.M., Jarvis W.R. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis. 167:1993;1247-1251.
5. Bekersky I., Boswell G.W., Hiles R., Fielding R.M., Buell D., Walsh T.J. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome®) in beagle dogs. Pharm. Res. 16:1999a;1694-1701.
6. Bekersky I., Fielding R.M., Buell D., Lawrence I. Lipid-based amphotericin B formulations: from animals to man. Pharm. Sci. Technol. Today. 2:1999b;230-236.
7. Bekersky I., Fielding R.M., Dressler D.E., Lee J.W., Buell D.N., Walsh T.J. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:2002;828-833.
8. Bhamra R., Sa'ad A., Bolcsak L.E., Janoff A.S., Swenson C.E. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob. Agents Chemother. 41:1997;886-892.
9. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta. 864:1986;257-304.
10. Boswell G.W., Bekersky I., Buell D., Hiles R., Walsh T.J. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 42:1998a;263-268.
11. Boswell G.W., Buell D., Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38:1998b;583-592.
12. Carrillo-Muñoz A.J., Quindõs G., Tur C., Ruesga M.T., Miranda Y., del Valle O., Cossum P.A., Wallace T.L. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J. Antimicrob. Chemother. 44:1999;397-401.
13. Fielding R.M., Smith P.C., Wang L.H., Porter J., Guo L.S.S. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35:1991;1208-1213.
14. Fukui H., Koike T., Saheki A., Sonoke S., Seki J. A novel delivery system for amphotericin B with lipid nano-sphere (LNS®). Int. J. Pharm. 265:2003a;37-45.
15. Fukui H., Koike T., Saheki A., Sonoke S., Tomli Y., Seki J. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS®). Int. J. Pharm. 263:2003b;51-60.
16. Gallis H.A., Drew R.H., Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:1990;308-329.
17. Guo L.S.S., Fielding R.M., Lasic D.D., Hamilton R.L., Mufson D. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int. J. Pharm. 75:1991;45-54.
18. Hiemenz J.W., Walsh T.J. Lipid formulations of amphotericin B. J. Liposome Res. 8:1998;443-467.
19. Hillery A.M. Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv. Drug Deliv. Rev. 24:1997;345-363.
20. Janoff A.S., Boni L.T., Popescu M.C., Minchey S.R., Cullis P.R., Madden T.D., Taraschi T., Gruner S.M., Shyamsunder E., Tate M.W., Mendelsohn R., Bonner D. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. U.S.A. 85:1988;6122-6126.
21. Kerridge D. Mode of action of clinically important antifungal drugs. Adv. Microb. Physiol. 27:1986;1-72.
22. Olsen S.J., Swerdel M.R., Blue B., Clark J.M., Bonner D.P. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 43:1991;831-835.
23. Otsubo T., Maesaki S., Hossain M.A., Yamamoto Y., Tomono K., Tashiro T., Seki J., Tomii Y., Sonoke S., Kohno S. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. Antimicrob. Agents Chemother. 43:1999;471-475.
24. Seki J., Sasaki H., Doi M., Yoshikawa H., Takahashi Y., Yamane S., Sonoke S., Yamamoto H., Hirose M., Ezure Y., Ando T., Ushimaru K., Sugiyama M. Lipid nano-sphere (LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration IV. J. Control. Release. 28:1994;352-353.
25. Szoka F., Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu. Rev. Biophys. Bioeng. 9:1980;467-508.
26. van Etten E.W.M., Otte-Lambillion M., ten Kate M.T., Bakker-Woudenberg I.A.J.M. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J. Antimicrob. Chemother. 35:1995;509-519.
27. Walsh T.J., Pizzo A. Treatment of systemic fungal infections: recent progress and current problems. Eur. J. Clin. Microbiol. Infect. Dis. 7:1988;460-475.
28. Wang L.H., Fielding R.M., Smith P.C., Guo L.S.S. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil®) and Fungizone® after repeated dosing in rats. Pharm. Res. 12:1995;275-283.
29. Yamazaki T., Kume H., Murase S., Yamashita E., Arisawa M. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J. Clin. Microbiol. 37:1999;1732-1738.